Nicholson R I, Colin P, Francis A B, Keshra R, Finlay P, Williams M, Elston C W, Blamey R W, Griffiths K
Cancer Res. 1986 Aug;46(8 Suppl):4299s-4302s.
An estrogen receptor enzyme immunoassay kit (ER-EIA) has been evaluated in 70 human breast carcinomas against a routine cytoplasmic [3H]estradiol binding assay (ERU). A linear correlation between the ER-EIA and the ERU was observed for binding values up to 400 fmol/mg of cytosol protein. Above this value, the ERU underestimates the concentration of receptor. The ERU gave a lower number of estrogen receptor-positive tumors (50 of 70) than did the ER-EIA assay (59 of 70). In the ERU-negative ER-EIA-positive tumors, receptor values as determined by the ER-EIA assay all fell below 50 fmol/mg of protein (mean, 19.9 +/- 4.2 fmol/mg of protein). Application of an exchange procedure which estimates the total steroid binding capacity of the cytosol gave positive results in 7 of 9 ERU-negative ER-EIA-positive tumors (mean, 16.9 +/- 2.95 fmol/mg of protein). Subdivision of the binding data according to the menopausal status of the patient indicates low receptor values in premenopausal women by each assay. A correlation between the ER-EIA assay and the histological grade of tumors was observed; Grade I well-differentiated tumors were all positive, while Grade II and III tumors were 86% and 75% positive, respectively. No correlation between the ER-EIA assay and tumor lymph node stage or tumor size was observed.
已使用雌激素受体酶免疫分析试剂盒（ER-EIA）对70例人类乳腺癌进行检测，并与常规细胞质[3H]雌二醇结合分析（ERU）进行对比。对于结合值高达400 fmol/mg胞浆蛋白的情况，观察到ER-EIA与ERU之间存在线性相关性。高于此值时，ERU会低估受体浓度。与ER-EIA分析（70例中有59例）相比，ERU检测出的雌激素受体阳性肿瘤数量较少（70例中有50例）。在ERU阴性但ER-EIA阳性的肿瘤中，通过ER-EIA分析测定的受体值均低于50 fmol/mg蛋白（平均值为19.9±4.2 fmol/mg蛋白）。采用一种估计胞浆总类固醇结合能力的交换程序，在9例ERU阴性但ER-EIA阳性的肿瘤中有7例得到阳性结果（平均值为16.9±2.95 fmol/mg蛋白）。根据患者的绝经状态对结合数据进行细分，结果表明每种分析方法检测出绝经前女性的受体值较低。观察到ER-EIA分析与肿瘤组织学分级之间存在相关性；I级高分化肿瘤均为阳性，而II级和III级肿瘤的阳性率分别为86%和75%。未观察到ER-EIA分析与肿瘤淋巴结分期或肿瘤大小之间存在相关性。
